Teva Pharmaceutical Industries announced that it has launched sales of irbesartan and irbesartan-hydrochlorothiazide tablets, two generic versions of Sanofi Aventis’ high blood pressure treatments. According to the company, the brand products had annual sales of approximately $464 million and $124 million in the United States, based on sales data from the IMS research firm. In addition, Teva has been awarded a 180-day period of marketing exclusivity.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Israel Foodtech Firms Meet UK Retailers, Investors In London
April 17, 2024
Facebook comments